Vivoryon Therapeutics to host R&D update call on July 18, 2024, discussing kidney disease progress and varoglutamstat's impact.
Vivoryon Therapeutics N.V., a clinical-stage company focused on protein modulation, will host a R&D update call on July 18, 2024, highlighting progress in kidney disease. The update will cover further analyses of varoglutamstat's impact on kidney function, an anticipated clinical development plan, and a Q&A session for investors and analysts. The call is expected to last 60 minutes.
July 09, 2024
5 Articles